Welcome to our dedicated page for XOMA Royalty Corporation news (Ticker: XOMA), a resource for investors and traders seeking the latest updates and insights on XOMA Royalty Corporation stock.
XOMA Royalty Corporation (NASDAQ: XOMA) operates as a biotechnology-focused royalty aggregator, providing non-dilutive funding to advance therapeutic development. This page serves as the definitive source for official company announcements and third-party analysis of XOMA's strategic partnerships, licensing agreements, and portfolio developments.
Investors and industry observers will find curated updates on milestone achievements, regulatory progress, and financial disclosures. Our aggregation includes press releases related to royalty acquisitions, clinical trial advancements, and commercial partnerships across XOMA's portfolio of innovative therapies.
The resource is particularly valuable for tracking payments tied to licensed assets in therapeutic areas including oncology and rare diseases. Users can expect updates on key business activities while avoiding promotional content or speculative analysis.
Bookmark this page for streamlined access to XOMA's latest developments. Combine regular visits with SEC filings and market data for comprehensive investment research.
XOMA Corporation has initiated an underwritten public offering of depositary shares, each representing a 1/1000th fractional interest in its Series B Cumulative Perpetual Preferred Stock, priced at a liquidation preference of $25.00 per depositary share. The offering, led by several financial institutions, will use net proceeds primarily for funding acquisitions related to drug development programs. XOMA's offering is registered under an effective Form S-3 with the SEC, and additional shares may be available for purchase by underwriters.
Viracta Therapeutics (Nasdaq: VIRX) and XOMA Corporation (Nasdaq: XOMA) announced the acquisition of milestone and royalty rights for two clinical-stage drug candidates through a $13.5 million upfront payment. XOMA may pay up to $20 million in milestone payments. The candidates include DAY101, in a Phase 2 trial for pediatric glioma, and vosaroxin, aimed at treating acute myeloid leukemia. This deal is expected to provide Viracta with non-dilutive capital to support upcoming trials for Epstein-Barr virus-related cancers.
XOMA Corporation (Nasdaq: XOMA) announced a cash dividend of $0.71875 per share for its Series A Cumulative Perpetual Preferred Stock (XOMAP). The dividend will be paid on or about April 15, 2021, to shareholders on record as of the close of business on April 2, 2021. This reflects the company’s ongoing commitment to returning value to its shareholders.
XOMA has developed a diverse portfolio licensed to other biotech firms, focusing on milestone and royalty opportunities within drug development.
XOMA Corporation reported a recognized revenue of $29.4 million for 2020, a significant increase from $18.4 million in 2019. The company achieved a milestone earning of $25 million following Novartis' Phase 2 trial initiation of NIS793 for metastatic pancreatic cancer. XOMA also completed a $24.6 million Series A Preferred Stock offering, paying an 8.625% dividend. As of December 31, 2020, XOMA held $84.2 million in cash, marking a solid financial position to support future operations and projects.
On February 23, 2021, XOMA Corporation announced that CEO Jim Neal will present at two upcoming investor conferences. He will participate in a panel at the Cowen 41st Annual Virtual Health Care Conference on March 2, 2021, discussing clinical development. Additionally, XOMA will present at the H.C. Wainwright Global Life Sciences Conference, with on-demand access starting March 9, 2021. XOMA specializes in a portfolio of partnered programs and antibody therapeutics, aiming to generate milestone and royalty revenues for shareholders.
XOMA Corporation (NASDAQ: XOMA) announced that CEO Jim Neal will present at two upcoming investor conferences. The H.C. Wainwright Virtual BioConnect 2021 Conference, running from January 11-14, 2021, will feature XOMA’s presentation available on-demand starting January 11 at 6:00 AM ET. Additionally, XOMA will present at the Biotech Showcase Digital Conference from January 11-15, 2021, accessible to registered participants. Replays of these presentations will be archived for 90 days on XOMA's investor relations website.
XOMA Corporation has successfully completed an underwritten public offering of 984,000 shares of its 8.625% Series A Cumulative Perpetual Preferred Stock at $25.00 per share, raising approximately $23.4 million in net proceeds. The funds will support a segregated dividend account and general corporate purposes, including future acquisitions related to drug development programs. The Preferred Stock trades under the symbol ‘XOMAP’ on Nasdaq. XOMA continues to expand its portfolio of partner-funded drug development programs across various therapeutic areas.
XOMA Corporation announced the pricing of its public offering of 880,000 shares of 8.625% Series A Cumulative Perpetual Preferred Stock at $25.00 per share, raising gross proceeds of $22.0 million. A 30-day option allows underwriters to purchase an additional 104,000 shares. The offering is set to close on December 15, 2020, subject to conditions. Proceeds will fund a segregated dividend account and support general corporate purposes, including acquiring milestone and royalty rights for drug development programs. The shares will trade under the symbol 'XOMAP' on NASDAQ if approved.
XOMA Corporation announced a public offering of its Series A Cumulative Perpetual Preferred Stock at a liquidation preference of $25.00 per share. The offering includes a 30-day option for underwriters to purchase additional shares. Proceeds will fund a segregated dividend account and support general corporate purposes, including acquisitions of milestone and royalty rights for drug development. The offering is conducted under an effective shelf registration statement. Joint book-runners for the offering include B. Riley Securities and others.
XOMA Corporation announced a $2 million milestone payment from Takeda, marking the first patient dosed in the Phase 2 study of mezagitamab for generalized myasthenia gravis. This collaboration began in 2006, and XOMA may receive up to $16 million more in milestones. Recently, XOMA earned $28.5 million from four partners for similar milestones. The company emphasizes its growing portfolio through milestone interests and royalty rights, indicating a promising future for its royalty aggregator model.
FAQ
What is the current stock price of XOMA Royalty Corporation (XOMA)?
What is the market cap of XOMA Royalty Corporation (XOMA)?
